Regentis Biomaterials Plans European Surgeon Training for GelrinC Launch

Regentis Biomaterials (NYSE American: RGNT) has announced plans to initiate European surgeon training activities in the third quarter of 2026 as part of its commercial launch strategy for GelrinC, a CE Mark-approved treatment for knee cartilage lesions. The hands-on training program is designed to provide orthopedic surgeons with practical experience using the cell-free implant, beginning at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.

The training initiative represents a critical step in the company's European commercialization strategy. It will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance, and knowledge sharing. GelrinC is a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes that expanding physician familiarity with the technology will facilitate adoption as the product enters broader clinical use.

GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the United States, where no off-the-shelf treatment is currently available. The European launch represents a significant milestone for the company, which is focused on regenerative medicine solutions for orthopedic applications.

According to the press release, the training program will help ensure that surgeons are proficient in the GelrinC procedure, potentially leading to improved patient outcomes and broader acceptance of the technology. The company's Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone.

For more information about the announcement, visit the full press release at https://ibn.fm/QOWWK. Updates on Regentis Biomaterials are available at the company's newsroom at https://ibn.fm/RGNT.